The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists

Jennifer Cole, Anthony Busti, Salahuddin Kazi

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The objective of this study was to evaluate the incidence of new onset or worsening congestive heart failure in Veteran's Affairs (VA) patients who have received infliximab, etanercept, or adalimumab, and to compare mortality rates in these patients to control populations. We enrolled three groups of patients for this retrospective study: TNF-α group (n = 103), a rheumatoid arthritis (RA) control group (n = 100), and a control group without RA (n = 100). All patients at our VA facility who had received at least one dose of the TNF-α antagonists were included in the TNF-α group. Admissions for CHF did not differ between the three groups: TNF-α 7 (6.7%), RA control 8 (8%), non-RA control 7 (7%); P = 0.940. Mortality rates were not significantly different: TNF-α 4 (3.8%), RA control 7 (7%), non-RA control 11 (11%); P = 0.147. Our study showed no difference between the three groups in either CHF exacerbation or mortality.

Original languageEnglish (US)
Pages (from-to)369-373
Number of pages5
JournalRheumatology International
Volume27
Issue number4
DOIs
StatePublished - Feb 2007

Fingerprint

Veterans
Rheumatoid Arthritis
Heart Failure
Tumor Necrosis Factor-alpha
Incidence
Arthritis
Mortality
Control Groups
Retrospective Studies
Population

Keywords

  • Congestive
  • Heart failure
  • Rheumatoid arthritis
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{b2f30306c6984a72b318f233f1d4b80f,
title = "The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists",
abstract = "The objective of this study was to evaluate the incidence of new onset or worsening congestive heart failure in Veteran's Affairs (VA) patients who have received infliximab, etanercept, or adalimumab, and to compare mortality rates in these patients to control populations. We enrolled three groups of patients for this retrospective study: TNF-α group (n = 103), a rheumatoid arthritis (RA) control group (n = 100), and a control group without RA (n = 100). All patients at our VA facility who had received at least one dose of the TNF-α antagonists were included in the TNF-α group. Admissions for CHF did not differ between the three groups: TNF-α 7 (6.7{\%}), RA control 8 (8{\%}), non-RA control 7 (7{\%}); P = 0.940. Mortality rates were not significantly different: TNF-α 4 (3.8{\%}), RA control 7 (7{\%}), non-RA control 11 (11{\%}); P = 0.147. Our study showed no difference between the three groups in either CHF exacerbation or mortality.",
keywords = "Congestive, Heart failure, Rheumatoid arthritis, Tumor necrosis factor",
author = "Jennifer Cole and Anthony Busti and Salahuddin Kazi",
year = "2007",
month = "2",
doi = "10.1007/s00296-006-0215-3",
language = "English (US)",
volume = "27",
pages = "369--373",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists

AU - Cole, Jennifer

AU - Busti, Anthony

AU - Kazi, Salahuddin

PY - 2007/2

Y1 - 2007/2

N2 - The objective of this study was to evaluate the incidence of new onset or worsening congestive heart failure in Veteran's Affairs (VA) patients who have received infliximab, etanercept, or adalimumab, and to compare mortality rates in these patients to control populations. We enrolled three groups of patients for this retrospective study: TNF-α group (n = 103), a rheumatoid arthritis (RA) control group (n = 100), and a control group without RA (n = 100). All patients at our VA facility who had received at least one dose of the TNF-α antagonists were included in the TNF-α group. Admissions for CHF did not differ between the three groups: TNF-α 7 (6.7%), RA control 8 (8%), non-RA control 7 (7%); P = 0.940. Mortality rates were not significantly different: TNF-α 4 (3.8%), RA control 7 (7%), non-RA control 11 (11%); P = 0.147. Our study showed no difference between the three groups in either CHF exacerbation or mortality.

AB - The objective of this study was to evaluate the incidence of new onset or worsening congestive heart failure in Veteran's Affairs (VA) patients who have received infliximab, etanercept, or adalimumab, and to compare mortality rates in these patients to control populations. We enrolled three groups of patients for this retrospective study: TNF-α group (n = 103), a rheumatoid arthritis (RA) control group (n = 100), and a control group without RA (n = 100). All patients at our VA facility who had received at least one dose of the TNF-α antagonists were included in the TNF-α group. Admissions for CHF did not differ between the three groups: TNF-α 7 (6.7%), RA control 8 (8%), non-RA control 7 (7%); P = 0.940. Mortality rates were not significantly different: TNF-α 4 (3.8%), RA control 7 (7%), non-RA control 11 (11%); P = 0.147. Our study showed no difference between the three groups in either CHF exacerbation or mortality.

KW - Congestive

KW - Heart failure

KW - Rheumatoid arthritis

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=33846278750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846278750&partnerID=8YFLogxK

U2 - 10.1007/s00296-006-0215-3

DO - 10.1007/s00296-006-0215-3

M3 - Article

C2 - 17028862

AN - SCOPUS:33846278750

VL - 27

SP - 369

EP - 373

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 4

ER -